Alkermes plc (NASDAQ:ALKS) Shares Bought by Fox Run Management L.L.C.

Fox Run Management L.L.C. grew its position in shares of Alkermes plc (NASDAQ:ALKS) by 426.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 66,862 shares of the company’s stock after acquiring an additional 54,172 shares during the quarter. Alkermes comprises about 0.3% of Fox Run Management L.L.C.’s investment portfolio, making the stock its 21st largest holding. Fox Run Management L.L.C.’s holdings in Alkermes were worth $1,923,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Venturi Wealth Management LLC acquired a new position in shares of Alkermes during the fourth quarter valued at $25,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Alkermes by 106.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company’s stock valued at $47,000 after acquiring an additional 842 shares during the period. Blue Trust Inc. raised its stake in shares of Alkermes by 2,231.5% during the fourth quarter. Blue Trust Inc. now owns 1,702 shares of the company’s stock valued at $49,000 after purchasing an additional 1,629 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in Alkermes by 558.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company’s stock worth $85,000 after purchasing an additional 2,502 shares during the period. Finally, KBC Group NV grew its position in Alkermes by 18.8% in the 3rd quarter. KBC Group NV now owns 4,890 shares of the company’s stock valued at $137,000 after buying an additional 774 shares in the last quarter. Institutional investors and hedge funds own 95.21% of the company’s stock.

Insider Activity

In other news, EVP Craig C. Hopkinson sold 144,419 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the completion of the transaction, the executive vice president now owns 57,875 shares of the company’s stock, valued at approximately $2,056,298.75. This represents a 71.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.89% of the stock is owned by company insiders.

Alkermes Stock Performance

Shares of ALKS opened at $34.60 on Friday. The company has a 50-day simple moving average of $32.97 and a 200-day simple moving average of $30.04. The firm has a market capitalization of $5.63 billion, a P/E ratio of 15.94, a P/E/G ratio of 2.20 and a beta of 0.62. Alkermes plc has a 52 week low of $22.90 and a 52 week high of $36.45.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. As a group, equities analysts forecast that Alkermes plc will post 1.31 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ALKS. HC Wainwright reiterated a “neutral” rating and issued a $46.00 price objective on shares of Alkermes in a report on Thursday, February 13th. UBS Group upgraded shares of Alkermes from a “sell” rating to a “neutral” rating and boosted their price target for the company from $21.00 to $38.00 in a report on Tuesday, March 4th. StockNews.com upgraded shares of Alkermes from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 13th. The Goldman Sachs Group boosted their price target on shares of Alkermes from $30.00 to $32.00 and gave the company a “buy” rating in a report on Friday, February 14th. Finally, Royal Bank of Canada began coverage on shares of Alkermes in a report on Thursday, March 13th. They set a “sector perform” rating and a $40.00 price target on the stock. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $38.46.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.